Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) have been given an average rating of “Buy” by the ten research firms that are presently covering the firm, MarketBeat.com reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have issued ratings on […]
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) has received an average recommendation of “Buy” from the ten analysts that are covering the company, MarketBeat reports. Ten investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have covered the stock in the last year […]
Bfsg LLC acquired a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,500 shares of the company’s stock, valued at approximately $30,000. A number of other hedge funds have also recently modified their holdings of FDMT. RA Capital Management L.P. boosted […]
Bfsg LLC acquired a new stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,500 shares of the company’s stock, valued at approximately $30,000. A number of other institutional investors and hedge funds […]
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) were down 2.3% during trading on Wednesday . The company traded as low as $26.13 and last traded at $26.13. Approximately 43,923 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 1,080,685 shares. The stock had previously […]